Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,443 across all filing types
Latest filing 2017-10-15 Investor Presentation
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Expert Briefing - Latest Clinical and Commercial Advances 2 pages 380.3KB
Investor Presentation Classification · 95% confidence The document is an announcement of an upcoming investor R&D briefing event featuring expert presentations and a Q&A session. It includes details such as date, time, location, speakers, and topics related to cancer immuno-oncology. There is no financial data, regulatory filing, or report content. The document is promotional and informational about a presentation event rather than a formal financial or regulatory report. Therefore, it fits best as an Investor Presentation (IP) type, as it focuses on company strategy, research, and market position for investors.
2017-10-15 English
Notice of Annual General Meeting & Proxy Form 19 pages 1.8MB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting and Explanatory Memorandum' and includes detailed information about the upcoming AGM, including date, time, location, resolutions to be voted on, voting exclusions, and explanatory notes for each resolution. It references the financial year ended 30 June 2017 and discusses the directors' remuneration report, re-election of directors, and approval of share options. The document is 15,000 characters long, indicating it is a full notice and explanatory memorandum rather than a brief announcement. The content aligns with materials typically provided to shareholders ahead of an AGM to inform them of the business to be conducted and to explain resolutions. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. It is not an Annual Report (10-K) or Remuneration Report (DEF 14A) itself, nor is it a voting results announcement (DVA). Therefore, the correct classification is AGM Information (AGM-R).
2017-10-12 English
Notice of Annual General Meeting/Proxy Form 18 pages 1.7MB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting and Explanatory Memorandum' and includes details about the date, time, and location of the AGM. It contains resolutions to be voted on at the AGM, such as the adoption of the directors' remuneration report, re-election of a director, and approval of issuing options to a director. The document also includes voting exclusion statements and explanatory notes related to the AGM agenda items. There is no actual financial data or full financial statements included; rather, it is a notice and explanatory material for the upcoming AGM. This matches the definition of 'AGM Information' which includes presentations and materials shared during the Annual General Meeting. The document length is substantial (15,000 characters), indicating it is not a brief announcement but detailed AGM materials. Therefore, the correct classification is AGM Information (AGM-R).
2017-10-11 English
IMU Receives $1.1m R&D Tax Refund 1 page 301.8KB
Regulatory Filings Classification · 95% confidence The document is a short announcement about Imugene Limited receiving a research and development tax refund of approximately $1.1 million. It includes company background information and contact details but does not contain any financial statements, detailed financial performance data, or regulatory filings. The document length is only 2052 characters, which is quite short and does not represent a full report. It is an announcement of a financial event (tax refund) rather than a detailed financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2017-10-10 English
Investor Presentation 36 pages 2.1MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Imugene Limited's mimotope induced B-cell antibodies for immuno-oncology, including executive summary, technology explanation, clinical trial phases, market opportunity, and pipeline development. It contains no financial statements, regulatory certifications, voting results, or legal proceedings. The content is structured as a presentation with slides, forward-looking statements, and detailed scientific and clinical information aimed at investors or stakeholders. There is no indication that this is an official annual or interim report, audit report, or earnings release. The document is not a brief factsheet or a simple announcement. Given the detailed nature and focus on company strategy, clinical progress, and market positioning, this fits the definition of an Investor Presentation (IP).
2017-10-05 English
Appendix 3B - ESOP 13 pages 294.1KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to securities issuance. The content includes detailed information about the class and number of securities issued, terms of the securities, issue price, purpose of the issue, shareholder approvals, and quotation agreements. It does not contain financial statements, earnings data, management discussion, or audit information. Instead, it focuses on capital raising and securities issuance details. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed issuance information, confirming it is not a mere announcement of a report but a substantive filing about capital changes.
2017-09-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.